logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost analysis of epilepsy surgery and of vigabatrin treatment in patients with refractory partial epilepsy.

    Article - En anglais

    Copyright (c) 1996 Elsevier Science B.V. All rights reserved.

    In this study the direct actual costs associated with epilepsy-related health care, treatment with the novel antiepileptic drug vigabatrin.

    (gamma-vinyl GABA, GVG & rpar ; epilepsy surgery evaluation (ESE & rpar ; and epilepsy surgery were analysed in 52 patients with intractable partial epilepsy who were on a waiting-list for ESE while trying GVG. Sixty percent of the 52 patients obtained a reduction in seizure frequency of 50% or more with GVG. Of the twenty-one operated patients 57% became seizure free, 10% had more than 75%, 5% had 50-75% and 29% had less than 50% reduction of seizure frequency. Of the 17 patients who did not go through ESE (the "" GVG responders "" & rpar ; the corresponding outcome was 6%, 59%, 29% and 6%. For the 14 patients who were neither operated nor GVG responders, the outcome was 0%, 0%, 36% and 64%. The mean yearly costs (expressed in 1991 prices & rpar ; of epilepsy-related health care including antiepileptic drug treatment was US $1594 the year before starting GVG therapy, and US $2959 the first year of GVG treatment including a mean yearly cost of GVG of US $1572. The mean total cost for ESE and surgery was US $46 778 (N=21 & rpar ; while the mean cost of ESE in patients evaluated but not accepted for surgery (N=14 & rpar ; was US $24 054. (...)

    Mots-clés Pascal : Epilepsie, Partiel, Réfractaire, Chirurgie, Vigabatrine, Coût, Analyse coût, Anticonvulsivant, Traitement, Chimiothérapie, Etude comparative, Homme, Système nerveux pathologie, Système nerveux central pathologie, Encéphale pathologie, Economie santé

    Mots-clés Pascal anglais : Epilepsy, Partial, Refractory, Surgery, Vigabatrin, Costs, Cost analysis, Anticonvulsant, Treatment, Chemotherapy, Comparative study, Human, Nervous system diseases, Central nervous system disease, Cerebral disorder, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0016612

    Code Inist : 002B02B06. Création : 21/05/1997.